Cargando…

Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1

Detalles Bibliográficos
Autores principales:	Das, Andrew B., Kakadia, Purvi M., Wojcik, Damian, Pemberton, Lucy, Browett, Peter J., Bohlander, Stefan K., Vissers, Margreet C. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775073/ https://www.ncbi.nlm.nih.gov/pubmed/31578317 http://dx.doi.org/10.1038/s41408-019-0242-4

Ejemplares similares

Efficient identification of somatic mutations in acute myeloid leukaemia using whole exome sequencing of fingernail derived DNA as germline control
por: Kakadia, Purvi M., et al.
Publicado: (2018)

Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate
por: Das, Andrew B., et al.
Publicado: (2020)

Ascorbate Inhibits Proliferation and Promotes Myeloid Differentiation in TP53-Mutant Leukemia
por: Smith-Díaz, Carlos C., et al.
Publicado: (2021)

TET2/IDH1/2/WT1 and NPM1 Mutations Influence the RUNX1 Expression Correlations in Acute Myeloid Leukemia
por: Pasca, Sergiu, et al.
Publicado: (2020)

Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia
por: Guan, Yihong, et al.
Publicado: (2020)

The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia
por: Nabil, Reem, et al.
Publicado: (2022)

WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients
por: Koczkodaj, Dorota, et al.
Publicado: (2022)

Erythrocyte Ascorbate Is a Potential Indicator of Steady-State Plasma Ascorbate Concentrations in Healthy Non-Fasting Individuals
por: M. Pullar, Juliet, et al.
Publicado: (2020)

Expression and prognosis analysis of TET family in acute myeloid leukemia
por: Zhang, Tingjuan, et al.
Publicado: (2020)

Ascorbate as a Co-Factor for Fe- and 2-Oxoglutarate Dependent Dioxygenases: Physiological Activity in Tumor Growth and Progression
por: Kuiper, Caroline, et al.
Publicado: (2014)

Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
por: Stölzel, Friedrich, et al.
Publicado: (2023)

Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs
por: Sharf, Giora, et al.
Publicado: (2020)

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
por: Rothenberg-Thurley, Maja, et al.
Publicado: (2018)

Spontaneous hematological remission of acute myeloid leukemia
por: Kaźmierczak, Maciej, et al.
Publicado: (2014)

Recurrent TET2 mutations in adult T cell leukemia
por: Marçais, Ambroise, et al.
Publicado: (2014)

TET2 mutations in acute myeloid leukemia: a comprehensive study in patients of Sindh, Pakistan
por: Shaikh, Abdul Rehman Khalil, et al.
Publicado: (2021)

Marginal Ascorbate Status (Hypovitaminosis C) Results in an Attenuated Response to Vitamin C Supplementation
por: Carr, Anitra C., et al.
Publicado: (2016)

Ascorbate availability affects tumor implantation-take rate and increases tumor rejection in Gulo(−/−) mice
por: Campbell, Elizabeth J, et al.
Publicado: (2016)

The concept of treatment-free remission in chronic myeloid leukemia
por: Saußele, S, et al.
Publicado: (2016)

What is treatment free remission in chronic myeloid leukemia?
por: Rea, Delphine, et al.
Publicado: (2017)

Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells
por: Shenoy, N, et al.
Publicado: (2017)

Crosstalk between b-catenin and WT1 signaling activity in acute myeloid leukemia
por: Wagstaff, Megan, et al.
Publicado: (2022)

FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia
por: Pašaliç, Z, et al.
Publicado: (2011)

Novel combined variants of WT1 and TET2 in a refractory and recurrent AML patient
por: Ma, Qiang, et al.
Publicado: (2021)

Ascorbic acid improves parthenogenetic embryo development through TET proteins in mice
por: Gao, Wei, et al.
Publicado: (2019)

Ascorbate Uptake and Retention by Breast Cancer Cell Lines and the Intracellular Distribution of Sodium-Dependent Vitamin C Transporter 2
por: Praditi, Citra, et al.
Publicado: (2023)

The Prognostic Significance of TET2 Single Nucleotide Polymorphism in Egyptian Chronic Myeloid Leukemia
por: Hamed, Nahla A., et al.
Publicado: (2020)

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia
por: Liu, Hongtao, et al.
Publicado: (2018)

Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
por: Hughes, Amy, et al.
Publicado: (2017)

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study
por: Bhatnagar, Bhavana, et al.
Publicado: (2023)

Clinical Implication of DNMT3A and TET2 Genes Mutations in Cytogenetically Normal Acute Myeloid Leukemia
por: Aref, Salah, et al.
Publicado: (2022)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

Spontaneous remission of acute myeloid leukemia with NF1 alteration
por: Bradley, Terrence, et al.
Publicado: (2020)

Spontaneous Remission of Acute Myeloid Leukemia: A Case Report
por: Martínez-Díez, Yolanda, et al.
Publicado: (2022)

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
por: Rocquain, Julien, et al.
Publicado: (2010)

Optimizing survival outcomes with post‐remission therapy in acute myeloid leukemia
por: Medeiros, Bruno C., et al.
Publicado: (2019)

The Anti-Leukemia Effect of Ascorbic Acid: From the Pro-Oxidant Potential to the Epigenetic Role in Acute Myeloid Leukemia
por: Travaglini, S., et al.
Publicado: (2022)

A 4‐gene expression score associated with high levels of Wilms Tumor‐1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia
por: Niavarani, Ahmadreza, et al.
Publicado: (2016)

An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia
por: Nakagawa, Natsuki, et al.
Publicado: (2022)

An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL
por: Kakadia, Purvi M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9ln4i97cafm4l34j8ucdtcoe47